Eris Lifesciences Q2 FY27 Revenue Up 12.6% to ₹892 Cr, PAT Soars 39.2% to ₹187 Cr
Eris Lifesciences reported Q2 FY27 consolidated revenue of ₹892 crore, up 12.6% YoY. PAT surged 39.2% to ₹187 crore. DBF revenue grew 14.1% to ₹809 crore. The company is advancing its diabetes pipeline, including Recombinant Semaglutide trials. ROCE improved to 19% and net debt reduced by ₹111 crore in H1.
The announcement details significant financial performance improvements, including double-digit revenue growth and substantial PAT increase, along with positive operational updates and pipeline advancements, which are highly material for investors.
The company reported strong year-on-year growth in revenue and a significant increase in profit after tax for both the quarter and half-year periods. Key business segments showed positive growth, and strategic initiatives like pipeline development and facility commercialization are progressing.
Eris Lifesciences Limited presented its investor presentation for Q2 and H1 FY27 on October 26, 2026. The company reported a consolidated revenue of ₹892 crore for Q2 FY27, marking a 12.6% year-on-year increase from ₹792 crore in Q2 FY26. Profit After Tax (PAT) saw a significant jump of 39.2% to ₹187 crore, compared to ₹134 crore in the same period last year. For the half-year ended September 30, 2026 (H1 FY27), consolidated revenue grew by 12.8% to ₹1,766 crore from ₹1,565 crore in H1 FY26, with PAT increasing by 27.3% to ₹330 crore from ₹260 crore.
The Domestic Branded Formulations (DBF) segment revenue grew by 14.1% YoY in Q2 FY27 to ₹809 crore, with an EBITDA margin of 35.7%. The company highlighted that excluding the impact of brands out-licensed to Zorvia Healthcare, the Q2 DBF growth would have been 16.5%, with an expected ~100 bps gross margin improvement going forward. The Bhopal facility has been commercialized, with vials and cartridges now in production, and a full manufacturing shift to Bhopal is expected in the second half of next year.
Eris Lifesciences' consolidated EBITDA for Q2 FY27 was ₹309 crore, a 7.3% increase YoY. The company's performance in major therapies, including diabetes, outgrew the market in Q2. Diabetes, which contributed 9.5% to the portfolio, saw a 37.3% growth in Q2. Eris is advancing its pipeline with India's first Recombinant Semaglutide trials and other analogs. The company also reported a reduction in debtor days to 70 in September 2026 from 80 in March 2026. The ROCE for FY27 year-to-date stood at 19%, up from 16% in FY26, with net debt reducing by approximately ₹111 crore in H1 FY27.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.